LAS VEGAS, June 22, 2020 (GLOBE NEWSWIRE) -- iBrands Corporation (OTC: IBRC) (“the Company”), a diversified holding and branding company, announces novel data suggesting that QuadraMune™ administration reduces the number and activity of immune inhibitory cells termed "myeloid suppressor cells."
In a series of animal studies using the triple-negative breast cancer 4T1 mouse model, the Company’s nutraceutical manufacturer, Therapeutics Solutions International, Inc. (TSOI), described through its filed patent preliminary data suggest that administration of QuadraMune™ reduced lung metastasis on its own and increased efficacy of a "cancer vaccine". These data suggest that the nutraceutical, which is currently being tested as a preventative immune booster to protect against COVID-19[1], may have potential use in oncology.
"The patent that we previously filed with the Company possessed data showing that QuadraMune™ suppresses inflammatory molecules which act to deteriorate antiviral immunity. Some of these molecules, we believe, activate myeloid suppressor cells," said Dr. James Veltmeyer, Chief Medical Officer of the manufacturer Therapeutics Solutions, co-inventor of the patent, and voted Top Doctor of San Diego in 2012, 2014, 2016, 2017, and 2019. "In the current patent, we cover the use of QuadraMune™ to reduce these immune inhibitory cells, called Myeloid Suppressor cells, which act as cancer's shield against the immune response."
The 2018 Nobel Prize in Medicine was awarded for the discovery of "checkpoint inhibitors" which are antibodies that suppress immune-suppressive molecule[2]. Based on the current data, QuadraMune™ appears to work through a similar mechanism.
"Myeloid Suppressor Cells, originally described by Dr. Sharwan Singhal as "Natural Suppressor" cells, have been shown to correlate with faster cancer death and treatment unresponsiveness," said Timothy Dixon, President, and CEO of the Company. "We are excited to be, to our knowledge, the only company that has developed a natural-based approach to these "cancer-helping" enemies of the immune system."
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
About iBrands Farms
iBrands Farms is a vertically integrated agribusiness focused on the production of hemp derived products with naturally occurring cannabinoids along with other nutraceutical products. Our mission is to efficiently deliver the highest quality products to our customers, both retail and B2B.
The company can be found at www.ibrandsfarms.com
About iBrands Corporation
iBrands Corporation, Inc. is a holding and branding company that acquires and operates niche market brands that have unique market positions within sectors that demonstrate return on investment potential. Business partnerships throughout the United States and Canada provide our brands many markets to expand into and produce consistently high growth rates for the next decade.
The company can be found at: www.ibrandscorporation.com
For more information please contact:
investorrelationsdesk@gmail.com
Safe Harbor Statement
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.
Sources:
[1] https://www.clinicaltrials.gov/ct2/show/NCT04421391
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303476/